Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Catapano, A.L
Right arrow Search for Related Content
PubMed
Right arrow Articles by Catapano, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Ezetimibe: a selective inhibitor of cholesterol absorption

A.L Catapano*

Dipartimento di Scienze Farmacologiche, Universita degli Studi di Milano, Milano, Italy

* Correspondence: Professor Alberico L. Catapano, PhD, Dipartimento di Scienze Farmacologiche, Universita degli Studi di Milano, Via G. Balzaretti, 9, Milano, 20133 Italy.

Abstract

Ezetimibe is a novel selective cholesterol absorption inhibitor that effectively blocks intestinal absorption of dietary and biliary cholesterol. Ezetimibe undergoes glucuronidation to a single metabolite and is localized in the intestinal wall, where it prevents cholesterol absorption. Enterohepatic recirculation of ezetimibe and the glucoronide ensures repeated delivery to the site of action and limits peripheral exposure. Ezetimibe does not affect the absorption of fat-soluble vitamins or triglycerides. Results from pre-clinical studies in various animal models have shown the lipid-lowering and anti-atherosclerotic properties of ezetimibe as a single agent, and a synergistic effect when combined with a statin. In cholesterol-fed rhesus monkeys, ezetimibe reduced both plasma cholesterol (ED50 = 0·0005 mg.kg–1.day–1) and low-density lipoprotein cholesterol levels in a dose-dependent manner. In apo F knockout mice, ezetimibe reduced serum cholesterol more than 50% and decreased carotid (97%) and aortic (47–87%) atherosclerosis. Ezetimibe inhibited the rise of plasma cholesterol in cholesterol-fed dogs (ED50 = 0·007 mg.kg–1.day–1). Co-administration of ezetimibe and lovastatin in chow-fed dogs synergistically reduced plasma cholesterol to levels lower than those achieved with either agent alone (). These results suggest that ezetimibe combined with a statin may similarly reduce plasma cholesterol levels in patients with hypercholesterolaemia.

Key Words: Cholesterol absorption inhibitor • ezetimibe • pre-clinical studies • atherosclerosis • hypercholesterolaemia • statins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.